$0.15
0.00%
Nasdaq, Nov 22, 03:30 pm CET
ISIN
CA45783P1027
Symbol
INNPF
Sector
Industry

InnoCan Pharma Stock price

$0.15
+0.04 38.77% 1M
-0.05 26.62% 6M
-0.15 51.20% YTD
-0.08 35.36% 1Y
-0.52 78.16% 3Y
-0.05 24.03% 5Y
-0.05 24.03% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.00 0.00%
ISIN
CA45783P1027
Symbol
INNPF
Sector
Industry

Key metrics

Market capitalization $42.01m
Enterprise Value $38.66m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.34
P/S ratio (TTM) P/S ratio 1.45
P/B ratio (TTM) P/B ratio 8.15
Revenue growth (TTM) Revenue growth 192.24%
Revenue (TTM) Revenue $28.93m
EBIT (operating result TTM) EBIT $-1.22m
Free Cash Flow (TTM) Free Cash Flow $-2.35m
Cash position $5.14m
EPS (TTM) EPS $-0.01
Show more

Is InnoCan Pharma a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Financial data from InnoCan Pharma

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
29 29
192% 192%
100%
- Direct Costs 2.86 2.86
-
10%
26 26
-
90%
- Selling and Administrative Expenses 26 26
114% 114%
88%
- Research and Development Expense 1.73 1.73
5% 5%
6%
-1.19 -1.19
75% 75%
-4%
- Depreciation and Amortization 0.04 0.04
0% 0%
0%
EBIT (Operating Income) EBIT -1.22 -1.22
74% 74%
-4%
Net Profit -2.60 -2.60
48% 48%
-9%

In millions USD.

Don't miss a Thing! We will send you all news about InnoCan Pharma directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

InnoCan Pharma Stock News

AD HOC NEWS
7 days ago
InnoCan Pharma Corporation / CA45783P1027
Neutral
MCAP MediaWire
about one month ago
Herzliya, Israel and Calgary, Alberta, October 21, 2024 – PRISM MediaWire – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in chronic pain management via Liposomal CBD drug products, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental
More InnoCan Pharma News

Company Profile

InnoCan Pharma Corp. operates as a pharmaceutical tech company. Its segments include: Pharmaceuticals and Consumer Wellness. The Pharmaceuticals segment focuses on developing innovative drug delivery platform technologies based on advanced cannabinoids science. It involves two drug delivery technologies: LPT CBD- loaded liposome platform and CLX CBD-loaded exosomes platform. The Consumer Wellness segment develops and markets a wide portfolio of innovative and self-care products to promote a healthier lifestyle. The company was founded in October 2017 and is headquartered in Alberta, Canada.

Head office Canada
CEO Iris Bincovich
Employees 9
Founded 2018
Website www.innocanpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today